By Elizabeth S. Eaton, Staff Writer | Mar 7, 2019 | 9:17 PM GMT
FDA said it no longer intends to retrospectively modify the names of biologics approved without an agency-designated suffix, according to updated draft guidance on the naming of biologics released Thursday.
Under the naming convention,
Read the full 336 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD